LAVAL, Quebec, Oct. 2, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced a partnership with the National Coalition Against Domestic Violence (NCADV) to help raise awareness of domestic violence. As part of the new domestic violence initiative, Valeant has pledged to donate a portion of sales from all Medicis and Obagi products to the NCADV in support of its initiatives.
"Domestic violence is an issue that affects us all, and in particular the number of women impacted every day is staggering," said J. Michael Pearson, chairman and chief executive officer. "This partnership provides a platform for us to partner with all stakeholders in the industry, from our employees to the medical community to the consumers who use our products, in the battle to end domestic violence. We are excited about the long-term prospects to improve the lives of women through this initiative."
"One in three women experience domestic violence in their lifetime. We can change those numbers dramatically if we all take action," says Rita Smith, executive director of the National Coalition Against Domestic Violence. "October is Domestic Violence Awareness Month and we are thrilled to be announcing our partnership with Valeant in the battle to end domestic violence. Together NCADV and Valeant will make a difference."
For additional information about this initiative, please visit: http://enddomesticviolence.valeant.com.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.
About National Coalition Against Domestic Violence
The National Coalition Against Domestic violence is a world-renowned agency whose work includes coalition building at the local, state, regional and national levels; support for the provision of community-based, non-violent alternatives - such as safe home and shelter programs - for battered women and their children; public education and technical assistance; policy development and innovative legislation; focus on the leadership of NCADV caucuses and task forces developed to represent the concerns of organizationally under-represented groups; and efforts to eradicate social conditions which contribute to violence against women and children.
Laurie W. Little
SOURCE Valeant Pharmaceuticals International, Inc.